PRESS RELEASE

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

Computational tool improves recombinant virus design efficiency and yield.

This innovative in-house development is a key component of Transgene's INTV[1] platform.

Poster to be presented at ESMO-AI 2025

Strasbourg, France, November 6, 2025, 8:30 a.m. CET – **Transgene (Euronext Paris: TNG),** a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announced it will **present a poster on its proprietary VacDesignR® computational tool at the upcoming ESMO AI & Digital Oncology 2025** conference, held in Berlin, Germany, from 12-14 November 2025.

The presentation will highlight how **VacDesignR® streamlines the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors**, enabling faster and more reliable manufacturing of individualized neoantigen therapeutic vaccines (**INTV**).
The individualized immunotherapies developed through the *myvac*® platform, currently being evaluated in a Phase I/II clinical trial (NCT04183166), are based on an MVA viral vector and their design already leverages the VacDesignR® tool.

Developed in-house, **VacDesignR® is a computational design engine that optimizes recombinant plasmid architecture for MVA vectors**, a core component of Transgene's *myvac*® platform. By minimizing unwanted homologous recombination and intelligently selecting peptide sequences for cassette assembly, VacDesignR® significantly improves production reliability and vector quality.

Future iterations of **VacDesignR® will incorporate AI-based components** to further improve performance and scalability, supporting Transgene's strategy to accelerate production timelines for individualized therapeutic vaccines, including its lead candidate TG4050 designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy.

"Participating at the first edition of the ESMO AI & Digital Oncology meeting highlights Transgene's pioneering role in combining viral vector-based individualized cancer vaccines with its vaccine design tool to optimize product performance and redefine the future of oncology treatment", commented **Maurizio Ceppi, Chief Scientific Officer of Transgene**.

[1] Individualized Therapeutic Neoantigen Vaccine

Title of the abstract: "VacDesignR®: a computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production"

Title of the poster: "VacDesignR®: a tool for optimizing recombinant poxvirus vaccine production"

- Poster and Abstract number: 385P
- Session: Drug development
- Date: November 12, 2025
- Author: B. Grellier

The poster presentation will take place on **November 12** at ESMO-AI conference and will be available that day on Transgene's website.

VacDesignR® is a computer-assisted method protected through patent and patent applications derived from WO2021/130210.

***

Contacts

Transgene:
Media:
Caroline Tosch
Corporate and Scientific Communications Manager
+33 (0)3 68 33 27 38
communication@transgene.fr

MEDiSTRAVA
Frazer Hall/Sylvie Berrebi
+ 44 (0)203 928 6900
transgene@medistrava.com

Investors & Analysts:
Lucie Larguier
Chief Financial Officer (CFO)
Nadege Bartoli
Investor Relations Analyst
and Financial Communications Officer
+33 (0)3 88 27 91 00/03
investorrelations@transgene.fr

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the *myvac*® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.

With Transgene's *myvac*® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations, identified and selected through advanced Artificial Intelligence technologies.

With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: www.transgene.com

Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene

About myvac®

myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. *myvac*®-derived products are designed to stimulate the patient's immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded "Investment for the Future" funding from Bpifrance for the development of its platform *myvac*®. TG4050 is the first *myvac*®-derived product being evaluated in clinical trials. Click here to watch a short video on *myvac*®.

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.